Stress gastritis revisited.
In current ICU populations, overt bleeding from stress gastritis occurs in 10% to 20% of patients. Bleeding rates may be reduced to about 3% in patients receiving prophylactic therapy. Although patients with bleeding have higher mortality rates than other critically ill patients, it is not clear that the mortality rate is improved with prophylactic therapy, as most patients die from their underlying disease. As new complications of prophylactic therapy are identified, better definitions of the population at risk to develop complications of stress gastritis will be necessary to select those patients who will benefit most from prophylactic therapy.
Trauma Division, St. Louis University School of Medicine, Missouri.
R M
RM
Durham
M J
MJ
Shapiro
D000863:Antacids / Q000009:adverse effects / Q000627:therapeutic use; D001639:Bicarbonates; D002927:Cimetidine / Q000009:adverse effects / Q000627:therapeutic use; D004848:Epithelium / Q000502:physiology; D005753:Gastric Mucosa / Q000098:blood supply / Q000503:physiopathology; D005756:Gastritis / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D007365:Intercellular Junctions / Q000502:physiology; D009093:Mucus / Q000502:physiology; D011453:Prostaglandins / Q000627:therapeutic use; D013312:Stress, Physiological / Q000150:complications* / Q000503:physiopathology; D013392:Sucralfate / Q000627:therapeutic use
D000863:Antacids; D001639:Bicarbonates; D006635:Histamine H2 Antagonists; D011453:Prostaglandins; D013392:Sucralfate; D002927:Cimetidine